Stem Cell Therapy for Stress Urinary Incontinence: Why Has Clinical Success Remained Limited?
- 1Department of Urogynecology and Vaginal Surgery, Federal University of São Paulo (UNIFESP/EPM), São Paulo, Brazil
Abstract
Introduction and Hypothesis: Stem cell therapy for stress urinary incontinence (SUI) has been pursued for more than a decade, supported by a compelling regenerative rationale and reassuring early-phase safety data. Yet clinical efficacy has remained modest, complete continence uncommon, and durability uncertain.
Method: In this Clinical Opinion, we argue that translation has stalled for reasons that are both biological and conceptual: heterogeneous cell products and manufacturing variability undermine reproducibility; endpoints and follow-up are insufficiently harmonized to benchmark against surgical standards; chronically fibrotic periurethral tissue may be biologically quiescent and poorly permissive for regenerative activation; and, fundamentally, continence is a biomechanical phenomenon that cell injections alone cannot replicate.
Results: We propose that future progress will depend on validated potency assays, mechanism-driven trial design, microenvironment priming strategies, and integration of regenerative biology with biomechanical reinforcement (e.g., scaffolds or biologically enhanced support constructs).
Conclusion: Until such integration occurs, stem cell therapy for SUI should remain investigational.
Related
- Past, Present, and Future Implantable Neuromodulation Treatments for Management of Urinary Urge Incontinence (UUI): Implications for Clinical Effectiveness and Safety
- Urinary Incontinence Among Community-Dwelling Older Women: An Exploratory Cross-Sectional Characterization of Clinical Features, Urinary Habits, and Perceptions
- Long-term effectiveness of app-based therapy for female urinary incontinence: 48-week follow-up of a randomised controlled trial
- Urinary incontinence in Ugandan gynecologic outpatient clinics: Prevalence, clinical types, and associated factors
- Post-Treatment Response and Safety of Stem Cell-Based Urethral Injection Therapy for Female Stress Urinary Incontinence: A Systematic Review and Meta-Analysis
BibTeX
@article{castro2026stem,
title = {{Stem Cell Therapy for Stress Urinary Incontinence: Why Has Clinical Success Remained Limited?}},
author = {Rodrigo A. Castro},
journal = {International Urogynecology Journal},
year = {2026},
month = aug,
doi = {10.1007/s00192-026-06830-1},
url = {https://doi.org/10.1007/s00192-026-06830-1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Stem Cell Therapy for Stress Urinary Incontinence: Why Has Clinical Success Remained Limited?
AU - Rodrigo A. Castro
PY - 2026
DA - 2026/08/22
JO - International Urogynecology Journal
DO - 10.1007/s00192-026-06830-1
UR - https://doi.org/10.1007/s00192-026-06830-1
AB - Introduction and Hypothesis: Stem cell therapy for stress urinary incontinence (SUI) has been pursued for more than a decade, supported by a compelling regenerative rationale and reassuring early-phase safety data. Yet clinical efficacy has remained modest, complete continence uncommon, and durability uncertain. Method: In this Clinical Opinion, we argue that translation has stalled for reasons that are both biological and conceptual: heterogeneous cell products and manufacturing variability undermine reproducibility; endpoints and follow-up are insufficiently harmonized to benchmark against surgical standards; chronically fibrotic periurethral tissue may be biologically quiescent and poorly permissive for regenerative activation; and, fundamentally, continence is a biomechanical phenomenon that cell injections alone cannot replicate. Results: We propose that future progress will depend on validated potency assays, mechanism-driven trial design, microenvironment priming strategies, and integration of regenerative biology with biomechanical reinforcement (e.g., scaffolds or biologically enhanced support constructs). Conclusion: Until such integration occurs, stem cell therapy for SUI should remain investigational.
SN - 0937-3462
SN - 1433-3023
ER -